Table 7.

Studies of inhaled ciprofloxacin in NCFB patients with P. aeruginosa present in sputum.

Study/Year	Preparation	Dose/Frequency	Duration	Patient Population	Key Outcomes after Treatment
Wilson 2013 [100]	CiDP	32.5 mg/BID	28 days	n = 24	Reduction in the bacterial load
Bilton 2010 [101]	ILC	150 mg or 300 mg/daily	28 days	n = 36	Both doses resulted in a reduction in the bacterial load
Bilton 2011 [102]	ILC	100 mg or 150 mg/daily	28 days	n = 96	Both doses resulted in a reduction in the bacterial load
Serisier 2013 [103]	ILC + CiSI	150 mg (ILC) + 60 mg (CiSI)/daily	28 days on, 28 days off (3 cycles)	n = 42	Delayed time to first pulmonary exacerbation and reduction in the bacterial load
Haworth 2017 [104]	ILC + CiSI	150 mg (ILC) + 60 mg (CiSI)/daily	28 days on, 28 days off (6 cycles)	n = 582	Increase in the median time to first exacerbation that required antibiotics and a decrease in the annual rate of exacerbations (regardless of the need of antibiotics)

BID, twice daily; CiDP, ciprofloxacin dry powder; CiSI, ciprofloxacin solution for inhalation; ILC, inhaled liposomal ciprofloxacin.